The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Living With HIV: Watch Aaron's Story
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Experimental Therapeutic HIV Vaccine Suppressed Virus by at Least 80% in Small Group of Patients, Study Says

November 30, 2004

An experimental therapeutic HIV vaccine suppressed the virus in a small group of HIV-positive Brazilians for up to a year, according to a study published Sunday in the online edition of the British journal Nature Medicine, the San Francisco Chronicle reports. Drs. Jean-Marie Andrieu and Wei Lu of the Institute of Research for Vaccines and Immunotherapies for Cancer and AIDS in Paris led the research. Researchers administered the vaccine -- which is designed to treat the virus rather than prevent infection -- to 18 HIV-positive Brazilians who had never taken any antiretroviral drugs (Russell, San Francisco Chronicle, 11/29). Every two weeks, the patients received injections that contained a mixture of their own dendritic cells -- a type of cell that is in the first line of defense in the immune system -- and whole HIV that had been chemically inactivated. Dendritic cells mark invaders with an antigen, or "tag," that helps to activate lymphocytes, another type of immune system cell, according to AFP/Independent Online. However, HIV is able to avoid being marked with antigens, and therefore evades detection by the immune system. The goal of the vaccine is to stimulate dendritic cells to recognize and mark the virus in order to mount a larger immune response (AFP/Independent Online, 11/29).

Four months after their first immunization, the patients' viral load levels were reduced by a median of 80%, Reuters reports. At the end of one year, eight of the patients had viral load levels that were 90% lower than their baseline levels (Reuters, 11/29). In addition, four patients' viral load levels were less than 1,000 copies per milliliter, a level so low that "in theory" means they "are not infective," Andrieu said, AFP/Independent Online reports. In addition, the patients' CD4+ T cell counts initially increased but fell back to their baseline levels. None of the patients experienced side effects (AFP/Independent Online, 11/29).

Costs, Next Steps
Currently, the vaccine is "impractical" to deliver to large numbers of people because it is "essentially custom made" for each patient, the Chronicle reports. Andrieu estimated that the cost of the treatment for one year could be $4,000 to $8,000 per person (San Francisco Chronicle, 11/29). Although the trial results suggest that this type of therapeutic vaccine shows potential to treat HIV-positive people, the researchers cautioned that additional research is necessary, Reuters reports. "We should emphasize ... that the efficacy of such a therapeutic vaccine will not be definitively proven until a randomized trial with an appropriate control arm has been performed," the researchers wrote (Reuters, 11/29).

Several CBS news programs reported on the French HIV vaccine research:

Back to other news for November 30, 2004

Reprinted with permission from You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at The Kaiser Daily HIV/AIDS Report is published for, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
See Also
More HIV News